These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas. Rieske P, Bartkowiak JK, Szadowska AM, Olborski B, Harezga-Bal B, Debiec-Rychter M. J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188 [Abstract] [Full Text] [Related]
5. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Landers JE, Cassel SL, George DL. Cancer Res; 1997 Aug 15; 57(16):3562-8. PubMed ID: 9270029 [Abstract] [Full Text] [Related]
6. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Bartel F, Taubert H, Harris LC. Cancer Cell; 2002 Jul 15; 2(1):9-15. PubMed ID: 12150820 [Abstract] [Full Text] [Related]
7. MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas. Schneider-Stock R, Walter H, Radig K, Rys J, Bosse A, Kuhnen C, Hoang-Vu C, Roessner A. J Cancer Res Clin Oncol; 1998 Jul 15; 124(10):532-40. PubMed ID: 9829856 [Abstract] [Full Text] [Related]
8. Expression of alternatively and aberrantly spliced transcripts of the MDM2 mRNA is not tumor-specific. Bartel F, Pinkert D, Fiedler W, Kappler M, Würl P, Schmidt H, Taubert H. Int J Oncol; 2004 Jan 15; 24(1):143-51. PubMed ID: 14654951 [Abstract] [Full Text] [Related]
9. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Chandler DS, Singh RK, Caldwell LC, Bitler JL, Lozano G. Cancer Res; 2006 Oct 01; 66(19):9502-8. PubMed ID: 17018606 [Abstract] [Full Text] [Related]
11. Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma. Dei Tos AP, Doglioni C, Piccinin S, Maestro R, Mentzel T, Barbareschi M, Boiocchi M, Fletcher CD. J Pathol; 1997 Jan 01; 181(1):8-13. PubMed ID: 9071997 [Abstract] [Full Text] [Related]
12. Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature. Boltze C, Schneider-Stock R, Jäger V, Roessner A. Pathol Res Pract; 2001 Jan 01; 197(8):563-8. PubMed ID: 11518050 [Abstract] [Full Text] [Related]
13. In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas. Bozzi F, Conca E, Laurini E, Posocco P, Lo Sardo A, Jocollè G, Sanfilippo R, Gronchi A, Perrone F, Tamborini E, Pelosi G, Pierotti MA, Maestro R, Pricl S, Pilotti S. Lab Invest; 2013 Nov 01; 93(11):1232-40. PubMed ID: 24018792 [Abstract] [Full Text] [Related]
20. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B. Cancer Res; 1993 May 15; 53(10 Suppl):2231-4. PubMed ID: 8387391 [Abstract] [Full Text] [Related] Page: [Next] [New Search]